WTO Reform Talks Begin in Cameroon Amid Global Trade Tensions 
SK Hynix Eyes Up to $14 Billion U.S. IPO to Fund AI Chip Expansion 
Intermittent fasting doesn’t have an edge for weight loss, but might still work for some 
Federal Reserve Balance Sheet Reduction: Brookings Research Outlines Possible Path Forward 
Middle East War Rattles Global Markets as Oil Tops $100 and Dollar Surges 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
Valero Port Arthur Refinery Explosion Prompts $1M Lawsuit Over Worker Safety Negligence 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
Wall Street Slides as Iran War Uncertainty, Oil Surge, and AI Fears Rattle Markets 
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Gold is meant to be a ‘safe haven’ in uncertain times. Why is it crashing amid a war? 
Lotte Biologics Co. will invest $48 million into its Syracuse, New York, plant to upgrade and boost its production capacity for drugs and antibody-drug conjugates.
The South Korean company purchased the factory from Bristol Myers Squibb for $160 million last year as part of its strategy to go overseas.
Lotte Biologics will hire some 70 new workers as part of plans to expand its facilities.
The Syracuse plant can annually produce 35,000 liters of drug substances.
Lotte Biologics has been beefing up its production capacity and plans to invest $3 billion to build a bio-industrial complex in South Korea by 2030, to post $3 billion in revenue.
